News
-
-
-
PRESS RELEASE
HBM Healthcare Investments once again delivered strong value growth in the 2025 calendar year despite currency headwind
HBM Healthcare Investments AG reports strong value growth despite currency headwind in 2025. NAV rose by 14.8% in Swiss francs. Profit of CHF 286 million expected for first nine months of 2025/2026 -
-
-
-
-
-
-
PRESS RELEASE
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million. Shareholders approved the takeover, with payment in cash and Mirum common stock, plus milestone payments